


These presentations were developed by the respective presenter(s), and the findings, interpretations, and conclusions contained or expressed with them do not necessarily reflect the views of BD. To the extent these presentations relate to specific products, such products should always be used in accordance with the relevant instructions for use and other product documentation. This content should not be copied or distributed without the consent of the copyright holder. For further information, please contact: GMB-EU-MDS@bd.com


# The importance of safety



*Gabriella De Carli, MD* on behalf of


the Italian Study Group on Occupational Risk of HIV (SIROH)

**MACOVA** 2020  
Multidisciplinary Advanced Course  
on Vascular Access



Department of Epidemiology, Pre-clinical Research and Advanced Diagnostics  
National Institute for Infectious Diseases "L. Spallanzani" - IRCCS, Rome, Italy

[www.inmi.it](http://www.inmi.it) - SIROH - [siroh@inmi.it](mailto:siroh@inmi.it)



*“Many nurses avoid as far as possible the care of infectious disease cases, and for two reasons: they realize their insufficient training and fear the possible consequences.*

*Both these obstacles can be removed by a thorough training in fever nursing which embraces a knowledge of the nature of infectious diseases, their mode of transmission and methods for prevention.*

*Fever nursing aims, fundamentally, at these two objects: the **intelligent care of the patient** in order that he may recover and the*

**Health and safety of HCW is paramount and closely linked to the health of patients**

Aseptic Fever Nursing

Author(s): D. L. Richardson

Source: *The American Journal of Nursing*, Vol. 15, No. 12

Published by: Lippincott Williams & Wilkins


Stable URL: <http://www.jstor.org/stable/3405284>

Accessed: 15-09-2017 15:08 UTC







**FIGURE. Number of confirmed cases (N = 58) of occupationally acquired HIV infection among health care workers reported to CDC — United States, 1985–2013**

10



## BLOODBORNE PATHOGENS

**UNIVERSAL PRECAUTIONS FOR THOSE OCCUPATIONALLY EXPOSED TO BLOOD OR OTHER POTENTIALLY INFECTIOUS MATERIALS**

<p><b>BE AWARE</b> Treat All Blood and Body Fluid as if They Were Infected With:</p> <ol style="list-style-type: none"> <li>1) HIV (Human Immunodeficiency Virus) Which Frequently Leads to <b>AIDS</b>.</li> <li>2) HIV I <b>HEPATITIS B</b> Virus).</li> <li>3) Other Bloodborne Pathogens (Microorganisms Found in Human Blood Which Can Cause Disease).</li> </ol>	<p><b>READ</b> Your Organization's Exposure Control Plan.</p>  <p><b>KNOW</b> Procedures, Practices, Vaccination Requirements, and Appropriate Reporting for Incidents of Exposure.</p>	<p><b>KNOW</b> Color Codings:</p> <ol style="list-style-type: none"> <li>1) Labels and Signs are Fluorescent Orange-Red with the Lettering or Symbol in a Contrasting Color</li> <li>2) Red Bags or Containers Don't Have to Be Labeled Since Their Red Color Indicates They May Contain Biohazards.</li> </ol> <p><b>READ</b> All Signs and Labels Carefully.</p>	<p><b>USE</b> Appropriate Personal Protective Equipment.</p> 
<b>GOAL: REDUCE TO ZERO YOUR RISK OF INFECTION</b>			
<p><b>ALWAYS</b> Wash Hands.</p> 	<p><b>NEVER</b> Recap, Bend, or Break Needles.</p> 	<p><b>DISPOSE</b> of Personal Protective Equipment and Contaminated Laundry.</p>	

**Awareness, Information, Education, Safe procedures for needle use & disposal, Ban of Recapping, Unnecessary use elimination, Provision of Training, Vaccination, PPE, & Safety Devices**

officer should realize the fact and *isolate all doubtful cases.*"

# The Brick Wall of Safety

Needle and Sharps Injuries Prevention

Patients' safety



**SAFETY-**  
**DE**

**Raisin**

**Re**  
**R**

**Inf**

**of**  
**needles**

**e**  
**up**

**ation**

**ective**  
**at**

$$P_{inf.} = P \times E \times F$$



**$P_{inf.}$**  = Probability to acquire an occupational infection

**P** = Probability that sources are BBV-infected (prevalence)

**E** = Efficacy of transmission

**F** = Frequency of exposure



# Raising Awareness

2017		Cumulative total <sup>a</sup>	Country, territory or area <sup>a</sup>
N	Rate		
			<b>EU/EEA</b>
270	3.1	9 543	Austria
890	7.9	30 618	Belgium
241	3.4	2 747	Bulgaria
106	2.5	1 538	Croatia
85	10.0	1 148	Cyprus
254	2.4	3 160	Czech Republic
242	4.2	7 591	Denmark
219	16.6	9 711	Estonia
158	2.9	3 911	Finland
5 211	7.8	83 306	France
-	-	60 688	Germany <sup>c</sup>
628	5.8	16 669	Greece
223	2.3	3 567	Hungary
24	7.2	385	Iceland
483	10.2	8 838	Ireland <sup>d</sup>
3 443	5.7	44 139	Italy
371	18.8	7 343	Latvia
0	0.0	67	Liechtenstein
263	9.1	3 012	Lithuania
59	10.2	1 641	Luxembourg <sup>d</sup>
45	10.4	432	Malta
716	4.2	26 129	Netherlands
213	4.1	6 291	Norway
1 325	3.5	22 798	Poland
1 068	10.3	57 913	Portugal
661	3.3	23 063	Romania
70	1.3	869	Slovakia
39	1.9	836	Slovenia
3 249	7.0	48 636	Spain
434	4.4	12 569	Sweden
4 363	6.7	155 267	United Kingdom
<b>25 353</b>	<b>5.8</b>	<b>654 425</b>	<b>Total EU/EEA</b>

**HIV**  
New diagnoses  
and rates per  
100 000  
population  
2008-2017

WHO (ECDC) 2018

Figure 6. Estimated number of HBsAg-positive individuals by country, based on general population prevalence estimates






Figure 7. Estimated number of anti-HCV-positive individuals by country, based on general population prevalence estimates



WHO (LSHTM) 2015

## HIV Seroconversion rate (SC), following exposure to blood SIROH, 1986-2017

	Type of exposure	SC/exp	% rate	95% CI
1986-1996 pre-HAART	<i>Percutaneous</i>	3/2066	<b>0.14</b>	0.03-0.42
	<i>Mucous cont.</i>	2/486	<b>0.41</b>	0.05-1.48
	<i>Non-intact skin</i>	0/547	<b>0</b>	-0.67
1997-2017 post-HAART	<i>Percutaneous</i>	1/1516	<b>0.07</b>	0.006-0.38
	<i>Mucous cont.</i>	0/727	<b>0</b>	-0.52
	<i>Non-intact skin</i>	0/285	<b>0</b>	-1.30





# HCV seroconversion (SC) rates, following exposure to blood SIROH, 1994-2017

HCV



Type of exposure (blood only)	SC/exp	% rate	95% CI
<b>Percutaneous exposure</b>	<b>41/13737</b>	<b>0.32</b>	<b>0.21-0.39</b>
<i>Hollow-bore, blood-filled needle</i>	<i>36/3640</i>	<i>1.00</i>	<i>0.69-1.36</i>
<i>Hollow-bore needle</i>	<i>1/3943</i>	<i>0.03</i>	<i>.006 -0.14</i>
<i>Solid needle/sharp</i>	<i>4/5860</i>	<i>0.07</i>	<i>.001-0.10</i>
<b>Mucous contamination</b>	<b>1/3887</b>	<b>0.03</b>	<b>.006-0.14</b>
<i>Conjunctival exp to blood</i>	<i>1/3060</i>	<i>0.04</i>	<i>.006-0.18</i>
<i>Other membranes to blood</i>	<i>0/827</i>	<i>0</i>	<i>-0.44</i>
<b>Non intact skin cont, with blood</b>	<b>0/1740</b>	<b>0</b>	<b>-0.20</b>


HBV



<b>Percutaneous exposure</b>	<b>1/347</b>	<b>0.30</b>	<b>.006-1.67</b>
Susceptible subjects (118 vaccinated after exposure)			

# H<sub>2</sub>B<sub>3</sub>V Vaccination

Fig. 4. Three-dose hepatitis B vaccine coverage, by WHO region, 2000–2015: a major increase in coverage at the beginning of the 21st century



Source: Joint UNICEF–WHO reporting form

# Cases of occupational infections or diseases acquired through a needle or sharps injury in the health care or laboratory setting (by year of publication of the first report in the literature)

Bacterial	Viral	Protozoal	Fungal	Tumoral
<ul style="list-style-type: none"> <li>• <i>Syphilis</i>, 1913</li> <li>• <i>Diphtheritis</i>, 1923</li> <li>• <i>Leptospirosis</i>, 1937</li> <li>• <i>Scrub typhus</i>, 1945</li> <li>• <i>Gonhorrea</i>, 1947</li> <li>• <i>Brucellosis</i>, 1966</li> <li>• Rocky Mountain Spotted Fever, 1967</li> <li>• <i>Mycoplasmosis</i>, 1971</li> <li>• <i>Mycobacteriosis</i>, 1977</li> <li>• <i>Rickettsia typhi</i>, 1978</li> <li>• <i>Staphylococcus aureus</i>, 1983</li> <li>• <i>Streptococcus pyogenes</i>, 1980</li> <li>• -Necrotizing fasciitis, 1997</li> <li>• Tuberculosis, 1931 (from a HIV-infected patient without acquiring HIV, 1998)</li> </ul>	<ul style="list-style-type: none"> <li>• Herpes simplex, 1962</li> <li>• <i>Haemorrhagic fevers</i> (Ebola, Marburg, Machupo, Sabia, etc), 1974</li> <li>• <i>Kyasanur virus</i>, 1975</li> <li>• Herpes Zoster, 1976</li> <li>• <i>Hepatitis B</i>, 1982</li> <li>• <i>Human Immunodeficiency Virus (HIV)</i>, 1984</li> <li>• Hepatitis D, 1986</li> <li>• <i>Creutzfeldt-Jakob</i>, 1988</li> <li>• <i>Herpesvirus simiae</i>, 1991</li> <li>• <i>Hepatitis C</i>, 1992</li> <li>• <i>Simian immunodeficiency virus</i>, 1994</li> <li>• <i>Dengue</i>, 1998</li> <li>• Hepatitis G, 1998</li> <li>• <i>West Nile virus</i>, 2002</li> <li>• Human T-lymphotropic Virus II, 2006</li> <li>• Chikungunya, 2006</li> <li>• <i>Hepatitis C Virus-NS3 recombinant vaccinia virus</i>, 2007</li> <li>• <i>Hepatitis E</i>, 2007</li> <li>• Cytomegalovirus, 2008</li> <li>• <i>Vaccinia virus</i>, 2008</li> <li>• Crimean Congo Haemorrhagic Fever, 2009</li> </ul>	<ul style="list-style-type: none"> <li>• <i>Toxoplasmosis</i>, 1951</li> <li>• <i>Malaria</i>, 1972</li> <li>• <i>Leishmaniasis</i>, 1997</li> <li>• <i>Trypanosomiasis</i>, 2001</li> </ul>	<ul style="list-style-type: none"> <li>• Blastomycosis, 1903</li> <li>• <i>Sporotrichosis</i>, 1977</li> <li>• Cryptococcosis, 1985 (from a HIV-infected patient without acquiring HIV, 1994)</li> </ul>	<ul style="list-style-type: none"> <li>• <i>Human colonic adenocarcinoma</i>, 1986</li> <li>• Sarcoma, 1996</li> </ul>

**Raising Awareness**

\*cases of pathogens or diseases enlisted in italics involved also or exclusively laboratory workers.

De Carli G, Abiteboul D, Puro V. Biochem Med (Zagreb) 2014; 24:45-56



Novel coronavirus




Disease X



Using a large-scale meta-transcriptomic approach, we discover 214 vertebrate-associated viruses in reptiles, amphibians, lungfish, ray-finned fish, cartilaginous fish and jawless fish. The newly discovered viruses appear in every family or genus of RNA virus associated with vertebrate infection, including those containing human pathogens such as influenza virus, the *Arenaviridae* and *Filoviridae* families. *Nature* 2018;556:197–202.

- Newly emerging diseases
- Re-emerging/resurgng diseases
- Deliberately emerging diseases
- Prioritized diseases WHO 2018



Morens DM, Folkers GK & Fauci AS. The challenge of emerging and re-emerging infectious diseases. *Nature* 2004;430:242–249.

**Raising Awareness**





# Epidemiology of Ebola virus disease transmission among health care workers in Sierra Leone, May to December 2014: a retrospective descriptive study

on an estimate  
12% were



25

IPC training was intensified

## Ebola Doctors Are Divided on IV Therapy in Africa

By DONALD G. McNEIL Jr. JAN. 1, 2015 NYT

Medical experts seeking to stem the Ebola epidemic are sharply divided over **whether most patients in West Africa should, or can, be given intravenous hydration**, a therapy that is standard in developed countries. [...]

The group's overwhelmed doctors do what they can, officials said, but **it is hard to insert needles while wearing three pairs of gloves and foggy goggles**. IVs must be monitored, drawing virus-laden blood for tests is dangerous, and patients yank needles out — sometimes in delirium, sometimes just to go to the toilet when no nurse is around.

**Doctors Without Borders normally puts IV lines in as many Ebola patients as it can manage**, said Dr. Armand Sprecher, an Ebola expert with the organization. **That practice was temporarily stopped in September, when the disease was spreading so fast that doctors had only one minute per patient** during the one hour they could work in their sweltering protective suits.

**Raising Awareness**

## Risk factors for acquiring an occupational infection following a percutaneous exposure


Risk factor	Added risk of acquiring HIV (adj. OR, CI 95%) <sup>1</sup>	Added risk of acquiring HCV (adj. OR, CI 95%) <sup>2</sup>
Deep injury	15,34 (6,01-41,05)	155,2 (7,1-3417,2)
Visible blood on the device	6,18 (2,15-20,74)	
Device posed in vein or artery	4,33 (1,71-11,89)	100,1 (7,3-1365,7)
Source patient with terminal illness	5,60 (1,99-16,06)	
Viremia > 6 log <sub>10</sub> cp/mL		11,0 (1,1-114,1)
Zidovudine PEP	0,19 (0,06-0,52)	
Male healthcare worker		3,1 (1,0-10,0)

<sup>1</sup>Cardo DM , Culver DH, Ciesielski CA et al. N Engl J Med 1997;337:1485-90


<sup>2</sup>Yazdanpanah Y , De Carli G, Miguères B et al. CI Infect Dis 2005; 41:1423-30.

# Map of risk: Device involved in NSI by area


Surgical area




Critical area




Medical area




Services



Laboratory




Non hospital setting



- Hollow-bore, blood-filled
- Hollow-bore, injection
- Lancet
- Suture
- Scalpel
- Sharps
- Glass objects

Map of risk

# Map of risk: Procedure being performed when the NSI occurred




ED: RR of sustaining a NSI with IV catheters vs other areas: 3.00 (CI 95% 1.95-3.75)

**Map of risk**



# Percutaneous exposures per 100 full-time equivalents, by job category and area

## SIROH, Italy




**Map of risk**

Puro V, De Carli G, Petrosillo N, Ippolito G and the SIROH Group. Infect Control Hosp Epidemiol 2001; 22:206-10.

# High-risk Percutaneous exposures per 100 FTE, by job category and area

## SIROH, Italy



- Housekeeper
- MD
- Nurse
- Midwife
- Technician
- GM general medicine
- MS medical specialties
- GS general surgery
- SS surgical specialties
- ID infectious diseases
- ICU intensive care
- is
- ory
- other

**Quantification**      **Characterization**      **Map of risk**

**Risk Assessment**

<b>Risk of infection</b> according to the amount of blood or other body fluid potentially inoculated through a needlestick or cut <b>(consequences)</b>	<b>Critical</b>	Fistula needle Spinal needle	IV catheter stylet	Phlebotomy needle	
	<b>Serious</b>	Thoracentesis Paracentesis	Scalpel	Lancet	Surgical instruments
	<b>Medium</b>	Culture inoculation (laboratory)	IV injection	IM injection	SC injection
	<b>Low</b>	Brain electrodes Electromyography electrodes	Needle for drug reconstitution/ preparation	Insulin pen needle	Suture needle
		<i>Rarely</i>	<i>Sometimes</i>	<i>Often</i>	<i>Frequently</i>
<b>Frequency of injury occurrence (likelihood)</b>					
<b>Adoption of safety devices integrating a protection mechanism <u>essential</u>.          Hepatitis B vaccination and staff education and training <u>mandatory</u>.</b>					
<b>Adoption of safety devices integrating a protection mechanism <u>recommended</u>.          Hepatitis B vaccination and staff education and training <u>mandatory</u>.</b>					
<b>Staff education and training to achieve the highest obtainable safety level. <u>Replacement with blunt needle, or needle elimination if alternatives are available.</u></b>					


# Risk Assessment





# SAFETY-ENGINEERED DEVICES

Percentage of SED used



NSI per 100,000 used devices (conventional and safety)

Years from introduction


◆ NSI rate      ■ Used SED

# The Needlestick Safety and Prevention Act (6/11/2000)

## Percutaneous Injuries before and after the Needlestick Safety and Prevention Act

23,908 injuries  
(85 hospitals in 10  
states)

Elayne K. Phillips, B.S.N., Ph.D.  
Mark R. Conaway, Ph.D.  
Janine C. Jagger, M.P.H., Ph.D.  
University of Virginia  
Charlottesville, VA  
ekp2e@virginia.edu



**Figure 1.** Annual Rates of Percutaneous Injuries per 100 Full-Time-Equivalent (FTE) Hospital Employees.


The mean ( $\pm$ SE) rates of percutaneous injuries obtained from 85 selected hospitals are plotted for each year during an 11-year period (1995 through 2005). After enactment of the Needlestick Safety and Prevention Act in 2001, the rates have steadily declined.

N ENGL J MED 366:7 NEJM.ORG FEBRUARY 16, 2012

**SAFETY-ENGINEERED  
DEVICES**

# Needlestick rates, conventional vs safety-engineered devices


22 SIROH hospitals, 1997-2010.



Proportion of safety devices use	56.1%	52.2%	60.1%	64.5%	66.4%	62.2%	64.2%	63.6%	67.9%
----------------------------------	-------	-------	-------	-------	-------	-------	-------	-------	-------

# Efficacy of safety hollow-bore, blood-filled devices

22 SIROH hospitals, 1997-2010




Baseline vs. Concurrent	0.001	0.028	0.005	0.085	0.257
Baseline vs. Safety active	<0.001	<0.001	<0.001	0.031	
Baseline vs. Safety passive			<0.001		<0.001
Concurrent vs. Safety active	<0.001	<0.001	<0.001	<0.0001	
Concurrent vs. Safety passive			<0.001		<0.001
Safety active vs. Safety passive			0.008		



# Needlestick rate per 100,000 IV catheters

## 10 hospitals, SIROH



Hospitals	10	10	8	8	7	6	3	2
Conventional Devices	480851	376100	346923	323404	305270	305649	61742	
Safety Engineered		79581	93370	108289	126447	110052	51912	22736

**2007 guideline for isolation precautions:  
preventing transmission of infectious**

**TABLE 4.  
RECOMMENDATIONS FOR APPLICATION OF STANDARD PRECAUTIONS FOR THE CARE OF ALL PATIENTS IN ALL  
HEALTHCARE SETTINGS  
(See Sections II.D.-II.J. and III.A.1)**

COMPONENT	RECOMMENDATIONS
Needles and other sharps	Do not recap, bend, break, or hand-manipulate used needles; if recapping is required, use a one-handed scoop technique only; use safety features when available; place used sharps in puncture-resistant container

E. Patchen Dellinger, MD, Professor of Surgery, University of Washington School of Medicine  
 Jeffrey Engel, MD, Head, General Communicable Disease Control Branch, North Carolina State Epidemiologist  
 Steven M. Gordon, MD, Chairman, Department of Infections Diseases, Hospital Epidemiologist, Cleveland Clinic Foundation  
 Lizzie J. Harrell, PhD, D(ABMM), Research Professor of Molecular Genetics, Microbiology and Pathology, Associate Director, Clinical Microbiology, Duke University Medical Center  
 Carol O'Boyle, PhD, RN, Assistant Professor, School of Nursing, University of Minnesota  
 David Alexander Pegues, MD, Division of Infectious Diseases, David Geffen School of Medicine at UCLA

Nebraska Medical Center

**HICPAC membership (past)**  
 Robert A. Weinstein, MD (Chair), Cook County Hospital, Chicago, IL  
 Jane D. Siegel, MD (Co-Chair), University of Texas Southwestern Medical Center, Dallas, TX  
 Michele L. Pearson, MD (Executive Secretary), Centers for Disease Control and Prevention, Atlanta, GA  
 Raymond Y.W. Chinn, MD, Sharp Memorial Hospital, San Diego, CA  
 Alfred DeMaria, Jr, MD, Massachusetts Department of Public Health, Jamaica Plain, MA  
 James T. Lee, MD, PhD, University of Minnesota, Minneapolis, MN  
 William A. Rutala, PhD, MPH, University of North Carolina Health Care System, Chapel Hill, NC  
 William E. Scheckler, MD, University of Wisconsin, Madison, WI  
 Beth H. Stover, RN, Kosair Children's Hospital, Louisville, KY  
 Marjorie A. Underwood, RN, BSN CIC, Mt. Diablo Medical Center, Concord, CA

(Am J Infect Control 2007;35:165-164.)  
 0196-6553/\$32.00  
 This is a U.S. Government work. There are no restrictions on its use.  
 doi:10.1016/j.ajic.2007.10.007

**Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the HICPAC. Am J Infect Control 2007;35:S65-164.**

# Needlestick Injury Rates According to Different Types of Safety-Engineered Devices: Results of a French Multicenter Study

TABLE 1. Needlestick Injury (NSI) Incidence Rates According to the Type of Safety-Engineered Device

Type of device	No. of devices purchased	No. of NSIs reported	No. of NSIs/1 × 10 <sup>5</sup> devices purchased
Insulin pen needles	22,540	0	0.00
Lancets	8,624,518	2	0.02
Arterial blood syringes	624,946	7	1.12
Prefilled syringes	4,342,861	55	1.27
Vacuum tube blood-collection devices	2,248,630	48	2.13
Fistula needles	45,156	1	2.21
Injection needles and/or syringes	184,207	5	2.71
Intravenous catheters	1,801,107	68	3.78
Winged steel needles	4,176,912	257	6.15
Implantable port needles	62,003	10	16.13

overall frequency of NSIs was 2.05 injuries per 100,000

# Prevention of Needle-Stick Injuries in Healthcare Facilities: A Meta-Analysis


Tarigan LH, Cifuentes M, Quinn M, Kriebel D. Infect Control Hosp Epidemiol. 2015 Jul;36(7):823-9.

Education/training (6 studies)  
-34% (0.66, 0.50-0.89)

Safety-Engineered Devices (SED) (5 studies)  
-49% (0.51, 0.40-0.64)

Education/training  
-62% (0.38, 0.28-0.48)

	RR*	LCL	UCL
2012	0.44	0.38	0.50
n, HF. 2011	0.41	0.14	1.21
09	0.60	0.43	0.84
2009	0.41	0.28	0.61
06	0.83	0.36	1.95
04	0.85	0.75	0.95
	<b>0.66</b>	<b>0.50</b>	<b>0.89</b>
	RR	LCL	UCL
08	0.64	0.46	0.88
F. 2007	0.26	0.13	0.51
	0.42	0.31	0.57
2004	0.53	0.37	0.76




Combining the 2 intervention approaches (training and SEDs) appears to be more effective than either intervention alone. This finding is in line with the conclusions of Ippolito et al,<sup>31</sup> who argued that successful NSI prevention needed to encompass many different interventions. Our finding that SEDs appear to be more effective than training was not surprising because SEDs reduce the exposure by modifying or isolating the hazard.<sup>32,33</sup> Training, in contrast, aims to reduce the risk by modifying the behavior of the subject (HCWs) without modifying the hazard from the devices.

**Education  
and Training**

**SAFETY-ENGINEERED  
DEVICES**






**“And so, without further ado, here’s the author of *Mind over Matter* ...”**

**It should be taken in mind that technological improvements can only be part of the solution. HCW must be aware, concerned and participate actively to reduce NSI to the best extent.**

# EU Directive on the prevention of sharps injuries: a joint effort



## Home > Gallery – Madrid Summit 2010



Stephen Hughes MEP, Grete Christensen, President of the European Federation of Nurses Associations (EFN), Cliff Williams Co-Chair EBS and Unison, Rudolph Cini, Vice-President of the International Council of Nurses (ICN), Dave Prentis General Secretary Unison



Dr Gabriella de Carli, Department of Epidemiology, National Institute for Infectious Diseases, Italy




Karen Jennings, Chair of the EPSU's Healthcare Committee and UNISON's Head of Healthcare



Dr Andreas Wittmann, Department of Safety Engineering, University of Wuppertal, Germany, Dr Janine Jagger Professor of Internal Medicine, University of Virginia, USA





- 
- **Health and safety of HCW** is paramount and closely **linked to the health of patients.**

To achieve the safest possible working environment, [we must:]

- set up an **integrated approach to prevention** from sharp injuries,
  - applying to **all** workers,
  - who should be **well trained, adequately resourced** and secure.
- **Never assuming that there is no risk,**
  - **employers and HCW shall work together**, to create a safe working environment, [for which]
  - a combination of **planning, awareness-raising, information, training, prevention and monitoring** measures is essential,
  - promoting a **no blame culture** in reporting.


# SAFETY-ENGINEERED DEVICES

## Needlestick-prevention devices implementation in 100 SIROH hospitals (June 2013)

Which type of risk assessment?


Answer:

- Analysis of NSI in previous years: 16 hospitals
- Risky procedure in high-risk unit: 10 hospitals
- Units with high prevalence of bloodborne pathogens: 2 hospitals







# Time trend of NSI by job category - SIROH, 1994-2016 (n=83883 out of 87540)



# Time trend of NSI by type of involved device - SIROH, 1994-2016



# Registered nurses: temporal trend of NSI by procedure




# Implementation of devices integrating a safety mechanism

## Italian National Safety Observatory – 2017 – 97 hospitals

**Nurses**  
n=180 

**Safety managers**  
n=135 



Not available 

Partial replacement 



# Sharp Decrease of Reported Occupational Blood and Body Fluid Exposures in French Hospitals, 2003–2012: Results of the French National Network Survey, AES-RAISIN

N. Floret, MD, PhD;<sup>1</sup> O. Ali-Brandmeyer;<sup>1</sup> F. L'Hériteau, MD;<sup>2</sup> C. Bervas, MD;<sup>3</sup> S. Barquins-Guichard;<sup>4</sup> G. Pelissier, PhD;<sup>5</sup> D. Abiteboul, MD;<sup>5</sup> P. Parneix, MD;<sup>3</sup> E. Bouvet, MD, PhD;<sup>2,5</sup> C. Rabaud, MD, PhD;<sup>1</sup> and Working Group AES-RAISIN




FIGURE 3. Trend in the proportion of healthcare facilities that have purchased more than 1 safety-engineered device among the 4 devices taken into account from 2008 to 2012 (intravascular catheters, blood gas syringes, needles for implanted ports, and unfractionated heparin syringes).

# Safety device use in UK: Changes since 2013 sharps regulations



**Table IV. Statistical comparison of 2013 and 2016 results**

	2013	2016	RR	CL95	p
<b>Activatable SED</b>					
Total (%)	1210 (100)	1826 (100)			
Correctly activated (%)	814 (67)	1413 (77)	1.15	1.10 - 1.20	<0.001
Partially or non-activated (%)	387 (32)	392 (22)	0.67	0.60 - 0.76	<0.001
Tampered with (%)	9 (1)	21 (1)	1.55	0.71 - 3.36	NS
<b>All HBN</b>					
Total (%)	2545 (100)	2959 (100)			
Uncapped needles & syringe-needles (%)	643 (25)	166 (6)	0.22	0.19 - 0.26	<0.001
Capped needles and syringe-needles (%)	127 (5)	42 (1)	0.82	0.60 - 1.12	NS
SED incl draw-up needles (%)	1775 (70)	2751 (93)	1.33	1.30 - 1.37	<0.001
Sharps discarded "sharp" (%)	1039 (41)	579 (20)	0.48	0.44 - 0.52	<0.001

SED safety engineered devices; HBN hollow bore needles

## Reduction of needlestick injuries by 48 % in 1 year : Effects of improvement of the safety concept according to the European Union Council directive 2010/32/EU at a large regional hospital

- In 2016 the NSI safety concept at a large regional hospital (Leverkusen, Germany) was improved according to 2010/32/EU, specifically by an update of blood screening profiles and standard operating procedures (SOP), better dissemination of information to employees and complete conversion to safety cannulas and scalpels.
- The **number of NSIs** in 2017 was significantly **reduced by 48.4%** as compared to 2016 and NSIs with scalpels were completely prevented.
- The proportion of employees with NSIs who were **adequately immunized against hepatitis B** was significantly **increased to 84.1%** in 2017.
- **Identification of the index patient** was significantly **increased to 82.5%** in 2017.
- The cost of avoiding NSIs increased by a total of **24.1%** in 2017 as compared to 2015 before introduction of the safety concept.

## Reduction of necessary needles

- Reduce the number of blood drawings/blood tests



- Reduce peripheral IV catheter insertion

- inserting an IV catheter without a clear indication, or a daily reassessment of its indications, represents a risk of infection for the patient, and the possibility of a NSI for the HCW when replacing the device.



- Reduce quote or length of IV/i.m./s.c. therapies

- administering a drug IM or IV when an oral therapy is feasible, increases the risk of infection for the patient, and the chance of a NSI for the HCW.





# Patients' safety





# Replacement of necessary needles

## Integration of new safety technologies for needle aspiration of breast cysts

Randy R. Sibbitt · Dennis J. Palmer ·  
Arthur D. Bankhurst · Wilmer L. Sibbitt Jr



**Fig. 1** Safety needle on the reciprocating procedure device (RPD). A BD safety needle with an off-axis rotating safety sheath was chosen as the safety device to reduce needlestick injuries and is shown here mounted on the RPD safety device. The BD needle comes with two sheaths (*left RPD*), a conventional sheath that is removed to expose and then use the needle (*middle RPD*), and then a lateral rotating sheath that is pushed with the finger and encloses and inactivates the used needle (*right RPD*)




**Fig. 2** Reciprocating procedure device (RPD). The RPD safety device for breast cyst aspiration injects when the thumb presses the dominant plunger and aspirates when the accessory plunger is pushed. The index and middle fingers do not change position on the finger flanges when transitioning from injection to aspiration. This results in an extremely well controlled and powerful safety device for breast cyst aspiration



# Elimination of unnecessary needles




- *Buttonhole* technique to access fistula in dialysis patients (blunt needles)




- sutureless fixing

## Non-invasive Epidermal Glucose Sensors




- Glucose sensor




- 2-way or multiple access to avoid piggyback





## Four good reasons to report an occupational exposure

- It is important for your own health: it allows the prompt administration of a prophylaxis, if available, or of a therapy whenever indicated, and the prevention of secondary transmission (spouse, family)
- It protects you: the epidemiological investigation allows to identify the source and the possible risks, and to demonstrate a causal relationship to receive workers' compensation in case an infection should develop;
- It allows to identify the causes and prevent other exposures: we need the data to support preventive interventions!
- .....It is mandatory by law



**Underreporting**

**Reporting & Recording**



# Response & follow up



[Back to Table of Contents](#)

[en](#) [es](#) [fr](#) [lit](#) [pt](#)

[Prev](#)

Eurosurveillance

## ORIGINAL ARTICLES

Eurosurveillance  
TOWARDS  
EUROPEAN

## Euroroundup

Citation  
for health  
/ViewAll

V Puro  
Euro

# EUROPEAN RECOMMENDATIONS FOR THE MANAGEMENT OF HEALTHCARE WORKERS OCCUPATIONALLY EXPOSED TO HEPATITIS B VIRUS AND HEPATITIS C VIRUS

1 Ist  
Rom

V Puro<sup>1</sup>, G De Carli<sup>1</sup>, S Cicalini<sup>1</sup>, F Soldani<sup>1</sup>, U Balslev<sup>2</sup>, J Begovac<sup>3</sup>, L Boaventura<sup>4</sup>, M Campins Martí<sup>5</sup>, MJ Hernández Navarrete<sup>6</sup>, R Kammerlander<sup>7</sup>, C Larsen<sup>8</sup>, F Lot<sup>9</sup>, S Lunding<sup>9</sup>, U Marcus<sup>10</sup>, L Payne<sup>11</sup>, AA Pereira<sup>4</sup>, T Thomas<sup>11</sup>, G Ippolito<sup>1</sup>

Anti-hepatitis  
man form  
When the  
discipl  
HIV

Exposure prevention is the primary strategy to reduce the risk of occupational bloodborne pathogen infections in healthcare workers (HCW). HCWs should be made aware of the medicolegal and clinical relevance of reporting an exposure, and have ready access to expert consultants to receive appropriate counselling, treatment and follow-up.

Vaccination against hepatitis B virus (HBV), and demonstration of immunisation before employment are strongly recommended. HCWs with postvaccinal anti-HBs levels, 1-2 months after vaccine completion,

### Introduction

Bloodborne pathogens such as hepatitis B (HBV) and C virus (HCV) represent an important hazard for healthcare workers (HCWs) [1]. In the general population, HCV prevalence varies geographically from about 0.5% in northern countries to 2% in Mediterranean countries, with some 5 million chronic carriers estimated in Europe; while HBV prevalence ranges from 0.3% to 3%. The World Health Organization (WHO) estimates that each year in Europe 304 000 HCWs are exposed to at least one percutaneous injury with a sharp



# How Much do Needlestick Injuries Cost? A Systematic Review of the Economic Evaluations of Needlestick and Sharps Injuries Among Healthcare Personnel

## Response & follow up

Alice Mannocci, PhD, MS;<sup>1</sup> Gabriella De Carli, MD;<sup>2</sup> Virginia Di Bari, PhD, MD;<sup>2</sup> Rosella Saulle, MD;<sup>1</sup> Brigid Unim, MD;<sup>1</sup> Nicola Nicolotti, MD;<sup>2</sup> Lorenzo Carbonari, PhD;<sup>3</sup> Vincenzo Puro, MD;<sup>2</sup> Giuseppe La Torre, DSc<sup>1</sup>

TABLE 4. Description of the Distribution of the Means of the Costs for Managing a Single Percutaneous Injury (2015 International US Dollars)

Approach	Type of Cost	No. of Studies	Means of the Costs for Managing a Single NSI				
			Median	Mean	SD	Min	Max
Data driven (N = 8)	Direct	5	173	521	610	48	1,516
	Indirect	3	175	232	119	152	369
	Direct + indirect	6	656	831	630	199	1,691
Modeling (N = 6)	Direct	4	586	595	285	294	913
	Indirect	3	322	346	59	303	413
	Direct + indirect	5	747	897	284	649	1,324
All (N = 14)	Direct	9	425	554	467	48	1,516
	Indirect	6	322	286	117	152	413
	Direct + indirect	11	747	861	482	199	1,691

NOTE. NSI, needlestick and sharps injury.

Direct + indirect costs = Int\$ **747** (range **199-1691**)

Direct costs (9 studies) = Int\$ 425 (48-1516); indirect costs (6 studies), Int\$322 (152-413).

Modeling studies had higher disaggregated and aggregated costs, but data-driven studies showed a greater variability

# Intangible costs of occupational injuries

- **Costs of intangible aspects of HCW injuries, such as anxiety and distress, could equal costs associated with the medical evaluation of these injuries**
- **The impact of being at risk of developing a bloodborne infection has effects on:**
  - personal and family life
  - sexual relationships
  - reproductive plans
  - breastfeeding
  - professional expectations



**Response & follow up**





PREMIO SHAM - FEDERSANITÀ ANCI  
PREVENZIONE DEI RISCHI 2017





# The Brick Wall of Safety

Needle and Sharps Injuries  
Prevention

Patients' safety

*Standard  
com*

*Protective  
ment*

**Monitoring**

**Elimin  
unnecessa**

**Audit & control**

*Vaccination*

**Raising Awareness**

**Education and  
Training**

**Recording &  
reporting of NS**

*ork Organization*

